Kexing Biopharm, a leading pharmaceutical company, has successfully concluded its participation at the renowned Kazakhstan International Healthcare Exhibition (KIHE) 2023, held at the Atakent International Exhibition Centre. With a sprawling exhibition area of 4551 square meters, KIHE attracted over 200 prominent pharmaceutical enterprises, solidifying its status as one of Kazakhstan's premier exhibitions.

Recently, the 5th Greater Bay Area Biopharmaceutical Innovators Summit has been held successfully in Guangzhou China. Kexing Biopharm Co., Ltd. (hereinafter referred to as "Kexing Biopharm", 688136. SH), as co-organizer , hosted the symposium -"Globalization of Biopharmaceutical, Investment, and Cooperation", inviting multiple industry veterans to discuss hot topics related to the deployment of biopharmaceuticals globalization business.

As internationalization gradually becomes the mainstream trend of development for China's biopharmaceutical industry, enterprises have intensified their efforts to go global, and the exchanges between the Chinese pharmaceutical....

Kexing Biopharmaceutical (688136.SH) has accomplished the impressive feat of being recognized on June 27 as one of "China's Top 20 Biopharmaceutical Enterprises" (blood products, vaccines and insulin) for two consecutive years.

Recently, Kexing Biopharm (688136.SH) has completed the first dose of its long-acting GC product, Pegylated Human Granulocyte Colony-stimulating Factor Injection (hereinafter referred to as long-acting GC) developed in China, in all enrolled subjects in Phase I clinical study, showing favorable safety and tolerability.

The 88th API China, a prestigious pharmaceutical event, took place at the Qingdao Cosmopolitan Exposition Exhibition Centre, where regional representatives from Kexing Biopharm's Overseas Marketing Division convened to participate.

Recently, Kexing Biopharm (688136.SH) signed with Chia-Tai Tianqing (CTTQ) an exclusive cooperation agreement for overseas commercialization of Trastuzumab for Injection recently. As a result, it has obtained the rights to commercialize the first batch of Trastuzumab for Injection in 12 countries.